Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369237 | 0.94 | GSK3B (0.89) | GSK3BCES1CA1CA2TDP1 | |
| Methylsulfanylmethane SCHEMBL28782214 | 0.94 | GSK3B (0.89) | GSK3BCES1CA1CA2TDP1 | |
| SCHEMBL40529 | 0.90 | GSK3B (0.81) | GSK3BCES1CA1CA2TDP1 | |
| Acetonitrile SCHEMBL27927677 | 0.90 | GSK3B (0.81) | GSK3BCES1CA1CA2TDP1 | |
| SCHEMBL298658 | 0.86 | GSK3B (0.73) | GSK3BTDP1ALDH1A1LMNA | |
| SCHEMBL18045554 | 0.85 | GSK3B (0.73) | GSK3BCES1CA1CA2TDP1 | |
| SCHEMBL240086 | 0.83 | GSK3B (0.71) | GSK3BCES1CA1CA2TDP1 | |
| SCHEMBL11510574 | 0.83 | GSK3B (0.71) | GSK3BCES1CA1CA2TDP1 | |
| Phenylacetaldehyde SCHEMBL11036118 | 0.83 | GSK3B (0.69) | GSK3BCES1TDP1ALDH1A1MAPK1 | |
| Hydrochlorthiazide SCHEMBL4937016 | 0.82 | GSK3B (0.68) | GSK3BCES1CA1CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116262673-B | Preparation method of alpha-bromoacetophenone compound | 浙江工业大学 | 2025-04-29 | — | — | CN | claimed |
| CN-119661534-A | Matrine aminothiazole derivative and preparation method and application thereof | 南京林业大学 | 2025-03-21 | — | — | CN | claimed |
| CN-115557865-B | Thioether-promoted cysteine-based bioconjugate method | 南京工业大学 | 2024-05-14 | — | — | CN | claimed |
| EP-3959200-B1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | ANADOLU UNIV (TR) | 2024-03-20 | — | — | EP | claimed |
| CN-117447490-A | Fluorescent probe with AIE (AIE) property, preparation method thereof and application of fluorescent probe in Al 3+ Application in recognition | 阜阳师范大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117343068-A | Preparation method of FGFR2 inhibitor Lirafugatinib (RLY-4008) | 上海相辉医药科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| EP-3958980-B1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | ANADOLU UNIV (TR) | 2023-11-15 | — | — | EP | claimed |
| CN-116179612-A | Method for efficiently catalyzing and synthesizing active VD3 through multienzyme coupling | 浙江中淬生物科技有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115557865-A | Thioether-promoted cysteine-based bioconjugation method | 南京工业大学 | 2023-01-03 | — | — | CN | claimed |
| EP-3958980-A1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | Anadolu Universitesi (TR) | 2022-03-02 | — | — | EP | claimed |
| WO-2006113367-A2 | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY | TGEN (US) | 2006-10-26 | — | — | WO | claimed |
| CN-1765503-A | Quarternary ammonium salt of quinine compound, its preparation method and use | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2006-05-03 | — | — | CN | claimed |
| US-20020061895-A1 | 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions | PHARMACEUTICAL INDUSTRY TECHNOLOGY | 2002-05-23 | — | — | US | claimed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | claimed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| EP-0542836-B1 | POLYMERIZATION OF SELECTED VINYL MONOMERS | DU PONT (US) | 1995-11-29 | — | — | EP | claimed |
| EP-0542836-A1 | POLYMERIZATION OF SELECTED VINYL MONOMERS. | DU PONT (US) | 1993-05-26 | — | — | EP | claimed |
| WO-1992002562-A1 | POLYMERIZATION OF SELECTED VINYL MONOMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-02-20 | — | — | WO | claimed |
| US-5086137-A | Polymerization of acrylic acids, esters and/or chloroprene using a diazoats or cyanate catalyst and a halogenated nitrile , ester or ketone activator | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061895-A1 | 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions | ATP6V1B1, GLS, RCC2 | GSK3B 4073/4885CES1 1802/4885CA1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.